

# KURARAY MEDICAL INC.

Dental Material Department 12-39, 1-Chome, Umeda, Kita-ku, Osaka 530-8611, JAPAN

Phone : +81-6-348-2603 Facsimile: +81-6-348-2552 K012734

SEP 1 4 2001

### 510(k) SUMMARY

1. Submitter

1) Name

KURARAY MEDICAL INC.

2) Address

1621 Sakazu, Kurashiki, Okayama 710-8622, Japan

3) Contact person

Koji Nishida

DENTAL MATERIAL DEPARTMENT

4) Date

August 9, 2001

5) Contact person in U.S.A.

Masaya Sasaki

30th Fl. Metlife Building, 200 Park Avenue, New York,

NY 10166

Telephone: (212)-986-2230

1-(800)-879-1676

Facsimile: (212)-867-3543

2. Name of Device

1) Proprietary Name

CLEARFIL NEW BOND

2) Classification Name

Resin tooth bonding agent (21CFR 872.3200)

3) Common/Usual Name

Resin-based dental adhesive system

#### 3. Predicate device:

Kuraray Co., Ltd. will transfer the medical device business and the relevant functions including manufacturing facilities to its subsidiary company named Kuraray Medical Inc. on October 1<sup>st</sup> 2001. The aim of 510(k) submission is to alter the name and address of manufacturer, and not to intend other changes.

The predicate device is as follow.

1. CLEARFIL NEW BOND by Kuraray Co., Ltd.

(K943167)

#### 4. Description for the premarket notification

CLEARFIL NEW BOND is classified into Resin tooth bonding agent, CFR 21 Section 872.3200, because it is a device composed of materials such as dimethacrylate monomers intended to be painted on the interior of a prepared cavity of a tooth to improve retention of a restoration, such as a filling. Normally composite resins and amalgams are used as filling material for this purpose.

#### 5. Statement of the intended use

The intended uses of this device are as follows. They are completely the same as CLEARFIL NEW BOND manufactured by Kuraray Co., Ltd. (K943167).

- 1) A dentin and enamel bonding system for composite resin restoration
- 2) A dentin and enamel bonding system for amalgam restoration

#### 6. Statement of the technological characteristics and safety

This device is essentially the same as CLEARFIL NEW BOND manufactured by Kuraray Co., Ltd. (K943167). Therefore the technological characteristics, chemical ingredients and safety of this device are completely the same as CLEARFIL NEW BOND.



SEP 1 4 2001

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Kuraray Medical Incorporated C/O Ms. Masaya Sasaki Kuraray America, Incorporated 30<sup>th</sup> Floor Metlife Building 200 Park Avenue New York, New York 10166

Re: K012734

Trade/Device Name: Clearfil New Bond

Regulation Number: 872.3200

Regulation Name: Resin-Based Dental Adhesive System

Regulatory Class: II Product Code: KLE Dated: August 9, 2001 Received: August 14, 2001

#### Dear Mr. Sasaki:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements

of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (section 531-542 of the Act; 21); CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Timothy A. Ulatowski

Director

Division of Dental, Infection Control and General Hospital Devices Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

K012734

510(k) Number (if known): // 0/2734

Device Name: CLEARFIL NEW BOND

## Indications for Use

CLEAFIL NEW BOND is indicated for the following applications:

- 1) A dentin and enamel bonding system for composite resin restoration
- 2) A dentin and enamel bonding system for amalgam restoration

(PLEASE DO NOT V	VRITE BELOW T	HIS LINE-CONTINU	E ON ANOTHER PAGE IF NEEI	)ED)
	Concurrence of	CDRH, Office of Dev	ice Evaluation (ODE)	
	* * * * * * * * * * * * * * * * * * *			
Prescription Use_		OR	Over-The-Counter Use	
(Part 21 CFR 801.	109)		(Ontional Form	mat 1 9 06\
			(Optional Form	nat 1-2-96)

(Division Sign-Off)
Division of Dental, Infection Control, and General Hospital Devices

510(k) Number \_